Medicare GLP-1 Bridge Program Launches to Improve Obesity Treatment Access

The Centers for Medicare & Medicaid Services (CMS) recently announced the upcoming launch of the Medicare GLP-1 Bridge program, set for July 1, 2026. This initiative aims to enhance access to semaglutide products, such as Wegovy® injections and tablets, for eligible Medicare beneficiaries managing obesity, with a reduced copayment of $50 per month. This marks a major step in increasing the accessibility of FDA-approved obesity treatments for Medicare patients.

Jamey Millar, executive vice president of US Operations at Novo Nordisk, emphasized the significance of the Medicare GLP-1 Bridge, noting obesity as a prevalent chronic illness among seniors. Millar stated, "We welcome the Medicare GLP-1 Bridge as an important step in getting Wegovy® to more patients. Collaborating with CMS, healthcare professionals, and patient advocates will aid in implementing this initiative and ensuring eligible seniors receive the care they need and deserve."

The program, applicable in all U.S. states and territories, provides access to all available Wegovy® formulations and runs through 2027. Patients can also utilize standard Part D benefits for cardiovascular-related indications. Novo Nordisk, in partnership with CMS, aims to streamline the implementation, engaging healthcare professionals and advocacy groups to raise awareness among eligible patients. Further details are available on the CMS website.

Novo Nordisk's ongoing commitment to widening access to effective medical treatments is evident in the Medicare GLP-1 Bridge initiative, offering affordable FDA-approved weight management solutions. For more information on semaglutide treatment affordability, consumers are encouraged to visit NovoCare.com. The company, with a century of expertise in diabetes care, prioritizes sustainable business practices across the United States.